UBS AM
ALDX icon

UBS AM’s Aldeyra Therapeutics ALDX Stock Holding History

UBS AM’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Hold
4,825
– – ﹤0.01% 3268
2026
Q1 		$8.15K Buy
4,825
+3,933
+441% +$17.2K ﹤0.01% 3356
2025
Q4 		$4.62K Buy
+892
New +$4.58K ﹤0.01% 2993
2023
Q4 		– Sell
-11,212
Closed -$74.9K – 2540
2023
Q3 		$74.9K Buy
+11,212
New +$83.2K ﹤0.01% 2574

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS AM's ALDX Position: Q2 2026 in Review

UBS AM held its Aldeyra Therapeutics (ALDX) position steady in Q2 2026 at 4,825 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3268.

UBS AM first reported a position in ALDX in Q3 2023 and has held it in 4 quarters since. The position peaked at $74.9K in Q3 2023. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • UBS AM held 4,825 shares of Aldeyra Therapeutics worth $10.3K as of Q2 2026.
  • UBS AM left its Aldeyra Therapeutics share count unchanged in Q2 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3268 holding.
  • UBS AM first reported a position in Aldeyra Therapeutics in Q3 2023 and has held it in 4 quarters since.
  • UBS AM's Aldeyra Therapeutics position peaked at $74.9K in Q3 2023.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.